How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti- multiple myeloma (MM ...

Daratumumab monotherapy may help prevent progression to active myeloma in patients with smoldering disease. New research findings are summarized in a short video.

How cancer patients feel physically before beginning treatment with daratumumab can predict how long they will live and how well they will respond to this multiple myeloma therapy, according to ...

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial ...

This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab. The daratumumab DRP ® was developed by correlating gene expression patterns with ...

This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab. The daratumumab DRP ® was developed by correlating gene expression patterns with ...